TLDR
- Tempus AI (TEM) surged 11.01% to $103.25, hitting an all-time intraday peak of $98.14
- Year-to-date gains reached 205.84% in 2025, with 114.75% growth over the past year
- FDA granted 510(k) clearance for the company’s RNA-based Tempus xR IVD device
- COO Ryan Fukushima’s spouse sold 5,000 shares worth $461,605 on October 6
- Nancy Pelosi’s January call options now valued at $415,000 from initial $50,000-$100,000 investment
Tempus AI shares closed at $103.25 on Wednesday, jumping 11.01% during the trading session. The health technology company hit an intraday all-time high of $98.14 before settling above the century mark.
The stock has posted remarkable gains in 2025. Year-to-date performance shows a 205.84% increase, while the past twelve months delivered 114.75% returns to investors.
Trading volume averaged 8.56 million shares daily. The company’s market capitalization reached $17.94 billion as of Wednesday’s close.
Shares have traded in a 52-week range between $31.36 and $103.42. After-hours trading added another 0.20%, pushing the price to $103.46.
FDA Approvals Drive Growth
The company secured 510(k) clearance from the FDA for its RNA-based Tempus xR IVD device. This tool will support drug development programs by detecting gene rearrangements in tumor tissues.
Tempus AI also received FDA clearance for an updated Tempus Pixel platform. The AI-driven cardiac imaging system expands the company’s diagnostic portfolio.
The CARE Program received an update incorporating breast density into the Tyrer-Cuzick breast cancer risk assessment model. This enhancement aims to refine screening recommendations for high-risk patients.
Revenue growth reached 59.84% over the last twelve months. Analysts have assigned price targets ranging from $60 to $100 for the stock.
Analyst Coverage and Ratings
Guggenheim raised its price target to $95 while maintaining a Buy rating. The firm’s upgrade followed discussions about oncology AI model development progress.
H.C. Wainwright lifted its target to $98 after the Tempus Pixel FDA clearance. InvestingPro assigned a “GOOD” financial health score to the company.
Benzinga’s Edge Stock Rankings placed momentum in the 93rd percentile. The metrics indicate positive price trends across all time frames.
Recent Insider Activity
Ryan Fukushima’s spouse sold 5,000 shares on October 6 for $461,605.58. The transaction occurred under a pre-arranged trading plan dated March 4.
SEC filings revealed average sale prices between $90.84 and $92.96. The spouse retained 130,000 shares following the transaction.
Fukushima directly owns 839,180 shares. Another 131,893 shares are held in the Ryan Fukushima Irrevocable Family Trust.
Former House Speaker Nancy Pelosi bought call options in January for $50,000 to $100,000. Those options are now worth approximately $415,000, representing over 300% gains.
